rozerem
ApprovedSmall molecule
rozerem is one of 83 small molecule programs targeting Parkinsonism. It is currently in Approved.
3
Indications
6
Total Trials
0
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
153 competitors in Insomnia
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsPhase 3
Elavil
AstraZenecaPhase 3
Neurontin
VViatris Specialty LLC
Phase 3
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Hetlioz
VVanda Pharmaceuticals
Phase 3
rozerem
SSouthern California Institute for Research and Education
Approved
Eplivanserin
SanofiPhase 3
Prosom
AAbbott
Phase 3
Org 50081
Merck & Co.Phase 3
MK0928, Gaboxadol
LundbeckPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Insomnia2 trials
Parkinson's Disease1 trial
Parkinsonism1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rozerem. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details